drugset
drugset / Trial / NCT00566449

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT00566449 ↗

Phase 2 Completed 32 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Timeline

Start
2007-12
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject bavisant Small molecule 10 mg Oral
Subject bavisant Small molecule 30 mg Oral

Indications

attention deficit-hyperactivity disorder